| Page 51 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia

Author(s): 
Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I, Aljurf M, Badawy SM, Beitinjaneh A, Boelens JJ, Diaz MA, Dvorak CC, Gadalla S, Gajewski J, Gale RP, Ganguly S, Gennery AR, George B, Gergis U, Gómez-Almaguer D
Primary Author: 
Bejanyan N
Journal Title: 
Blood Advances
Original Publication Date: 
Oct 2019

Allogeneic bone marrow transplantation (BMT) is curative therapy for the treatment of patients with severe

Bone Marrow Disease(s): 

When Your Child With a Rare Disease Doesn’t Feel Brave

Have you ever done something that you knew was the right thing to do, but you were scared to do it? Or maybe you did something that looked hard, but you decided to try it. That is courage in action and you probably felt very good about what you did. And you should!

Courage shows up in many ways all around you. Courage is standing up for a friend, helping someone in need or sticking with something that is hard for you to do. They say that having courage makes you a better person, and courage is one of the most important faculties you can develop.  

Using Integrative Medicine to help patients through Treatment- a recent conversation with Dr. M. Kogan

Dr. Mikhail Kogan, Medical Director of the GW Center for Integrative Medicine, discusses incorporating Integrative Medicine into a patient's treatment plan. He describes using yoga, meditation, and other techniques to help patients while they are in treatment for bone marrow failure conditions.

Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria

Author(s): 
Stern RM, Connell NT
Primary Author: 
Stern RM
Journal Title: 
Therapeutic Advances in Hematology
Original Publication Date: 
Sep 2019

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare stem cell disorder characterized by

Bone Marrow Disease(s): 

Germline DDX41 mutations define a significant entity within adult MDS/AML patients

Author(s): 
Sébert M, Passet M, Raimbault A, Rahmé R, Raffoux E, Sicre de Fontbrune F, Cerrano M, Quentin S, Vasquez N, Da Costa M, Boissel N, Dombret H, Peffault de Latour R, Socié G, Itzykson R, Fenaux P, Soulier J, Adès L, Clappier E
Primary Author: 
Sebert M
Journal Title: 
Blood
Original Publication Date: 
Sep 2019

Germline DDX41 mutations are involved in familial

Bone Marrow Disease(s): 

Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes

Author(s): 
Santini V, Valcárcel D, Platzbecker U, Komrokji RS, Cleverly A, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Sridharan A, Gueorguieva I, Girvan A, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Will B, Verm A
Primary Author: 
Santini V
Journal Title: 
Clinical Cancer Research: an official Journal of the American Association of Cancer Research
Original Publication Date: 
Sep 2019

PURPOSE:

Bone Marrow Disease(s): 

Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Author(s): 
Loghavi S, Wang SA
Primary Author: 
Loghavi S
Journal Title: 
Surgical Pathology Clinic
Original Publication Date: 
Jul 2019

In this article we provide a practical and comprehensive review of myeloid neoplasms with overlapping myelodysplastic (MDS) and myeloproliferative (MPN) features, with emphasis on recent updates in classification, particularly the utility of morphologic, cytogenetic, and molecular findings in better defining and classifying these disease entities.

Bone Marrow Disease(s):